MDACC Study No:2011-0827 ( NCT No: NCT01496495)
Title:A Phase 1 Study of ARRY-614 in Patients with Low or Intermediate-1 Risk
Myelodysplastic Syndromes
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:ARRY-614
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of ARRY-614 that can be given to patients with MDS either 1 or 2 times a day.

ARRY-614 is designed to block the function of certain proteins that cause
normal blood cells to die in patients with MDS. This could cause the normal
blood cells to survive.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:ARRY-614
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Array BioPharma
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults